Lisa Lawrence-Miyasaki, RN, BSN, MA has been in the pharmaceutical industry for 21+ years, most recently as Head of Pharmacovigilance and Clinical Drug Safety at Coherus BioSciences to develop and commercialize biosimilar drugs in a new pharmaceutical category supported by regulators in the U.S., Europe and Asia. Ms. Lawrence-Miyasaki has more than 10 years of clinical experience as a registered nurse, primarily in the transplant (heart, liver, kidney) intensive care unit at California Pacific Medical Center, San Francisco, California. She worked at Genentech, Inc. for over 14 years where she was the Senior Drug Safety Scientist (safety lead) for thrombolytics, anti-IgE, ranibizumab, dornase alfa and other Genentech products. From 2011 to 2017, as the head of Global Pharmacovigilance, The Americas, she shared oversight of the Santen global PV system and was responsible for creation of global organizational strategy, goals, and objectives and implementation of local and global safety strategies.